Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study

Reuters01-06

Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study

Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The initial results, which were presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, demonstrated reductions in parenteral support (PS) ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1124314) on January 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601281899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601281899","market":"nz","top_or_hot":-1,"title":"Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The initial results, which were presented on November 8, 2025, at the <a href=\"https://laohu8.com/S/FNCSF\">North American</a> Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, demonstrated reductions in parenteral support (PS) ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1124314) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The initial results, which were presented on November 8, 2025, at the <a href=\"https://laohu8.com/S/FNCSF\">North American</a> Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, demonstrated reductions in parenteral support (PS) ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1124314) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL5y78zh:1","article_id":"2601281899","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601281899","pubTimestamp":1767708072,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome  and microvillus inclusion disease . The initial results, which were presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition  Annual Meeting, demonstrated reductions in parenteral support  ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","JAGX":"Jaguar Animal Health, Inc."},"translate_title":"Jaguar Health报告Crofelemer减少儿科肠外支持研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":0.9},"content_text":"Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study\n    \n\n        Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The initial results, which were presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, demonstrated reductions in parenteral support (PS) ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1124314) on January 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601281899","isCrawlerRequest":true}